February 1, 2022
Life Sciences
  • Pfizer and BioNTech are expected to soon ask the FDA to grant an emergency use authorization for their two-dose vaccine that can be administered to children under the age of five. According to sources familiar with the matter, the FDA urged the companies to submit their request so that regulators could review the data on the vaccine. If approved, the two-dose regimen of the vaccine could be available to young children by the end of February. (Articles here and here)